Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab.
Adalimumab
Advanced therapy
Real world
Switching
Treatment persistence
Ustekinumab
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
received:
03
05
2024
accepted:
02
07
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
14
8
2024
Statut:
aheadofprint
Résumé
Persistence on advanced therapies in ulcerative colitis (UC) is a useful real-world treatment performance measure. This study compared real-world persistence during the maintenance phase among advanced therapy-naïve and -experienced patients with UC initiated on ustekinumab or adalimumab. Claims data from the IQVIA PharMetrics At 12 months post-index, advanced therapy-naïve patients receiving ustekinumab (n = 371) had higher persistence on the index agent [83.8% vs. 57.6%, hazard ratio (95% confidence interval) = 3.09 (2.29-4.16); p < 0.001), persistence while corticosteroid-free [2.00 (1.63-2.45); p < 0.001], persistence while on monotherapy [2.67 (2.07-3.44); p < 0.001], and persistence on the labeled dose [4.21 (2.76-6.44); p < 0.001] versus those receiving adalimumab (n = 1726). At 12 months post-index, advanced therapy-experienced patients receiving ustekinumab (n = 693) had higher persistence on the index agent [78.1% vs. 59.2%, 2.44 (1.82-3.26); p < 0.001], persistence while corticosteroid-free [1.24 (1.01-1.54); p = 0.0447], persistence while on monotherapy [2.53 (2.00-3.21); p < 0.001], and persistence on the labeled dose [4.77 (3.09-7.35); p < 0.001] versus those receiving adalimumab (n = 254). This claims-based analysis demonstrated significantly higher treatment persistence, including persistence while corticosteroid-free, persistence while on monotherapy, and persistence on the labeled dose, among both advanced therapy-naïve and advanced therapy-experienced patients with UC initiated on ustekinumab compared to adalimumab.
Identifiants
pubmed: 39141283
doi: 10.1007/s12325-024-02942-6
pii: 10.1007/s12325-024-02942-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Aslam N, Lo SW, Sikafi R, et al. A review of the therapeutic management of ulcerative colitis. Therap Adv Gastroenterol. 2022;15:17562848221138160. https://doi.org/10.1177/17562848221138160 .
doi: 10.1177/17562848221138160
pubmed: 36478780
pmcid: 9720837
Ye Y, Manne S, Treem WR, et al. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflamm Bowel Dis. 2020;26(4):619–25. https://doi.org/10.1093/ibd/izz182 .
doi: 10.1093/ibd/izz182
pubmed: 31504515
Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152 .
doi: 10.14309/ajg.0000000000000152
pubmed: 30840605
AbbVie Inc. RINVOQ
Bristol Myers Squibb Company. ZEPOSIA
Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–61. https://doi.org/10.1053/j.gastro.2020.01.006 .
doi: 10.1053/j.gastro.2020.01.006
pubmed: 31945371
Abbott. Abbott's Humira
Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–14. https://doi.org/10.1056/NEJMoa1900750 .
doi: 10.1056/NEJMoa1900750
pubmed: 31553833
US Food and Drug Administration. BLA 761044/S-003 BLA 125261/S-152 Supplement Approval 2019. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761044Orig1s003,%20125261Orig1s152ltr.pdf . Accessed 12 Feb 2024.
Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7. https://doi.org/10.1136/gut.2010.221127 .
doi: 10.1136/gut.2010.221127
pubmed: 21209123
Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257 e1-265. https://doi.org/10.1053/j.gastro.2011.10.032 .
doi: 10.1053/j.gastro.2011.10.032
Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS ONE. 2020;15(1): e0227914. https://doi.org/10.1371/journal.pone.0227914 .
doi: 10.1371/journal.pone.0227914
pubmed: 31945774
pmcid: 6964980
Sah J, Teeple A, Muser E, et al. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases. Curr Med Res Opin. 2022;38(7):1093–101. https://doi.org/10.1080/03007995.2022.2071041 .
doi: 10.1080/03007995.2022.2071041
pubmed: 35475385
Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507. https://doi.org/10.1111/jcpt.12830 .
doi: 10.1111/jcpt.12830
pubmed: 30873648
Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–27. https://doi.org/10.1093/ibd/izz001 .
doi: 10.1093/ibd/izz001
pubmed: 30839057
Goss Sawhney T, Dobes A, O’Charoen S. Real-world persistency for inflammatory bowel disease biologics using patient registry data. Crohns Colitis 360. 2023;5(4):otad051. https://doi.org/10.1093/crocol/otad051 .
doi: 10.1093/crocol/otad051
pubmed: 37941597
pmcid: 10629214
Janssen Pharmaceutical Companies. STELARA
Zhdanava M, Ding Z, Manceur AM, et al. Treatment persistence among bio-naïve patients with Crohn’s disease initiated on ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(4):533–43. https://doi.org/10.1080/03007995.2023.2178148 .
doi: 10.1080/03007995.2023.2178148
pubmed: 36752586
Zhdanava M, Zhao R, Manceur AM, et al. Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab. J Manag Care Spec Pharm. 2023;29(8):907–16. https://doi.org/10.18553/jmcp.2023.29.8.907 .
doi: 10.18553/jmcp.2023.29.8.907
pubmed: 37523319
pmcid: 10397324
Xu C, Ferrante SA, Fitzgerald T, et al. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29(1):90–100. https://doi.org/10.18553/jmcp.2023.29.1.90 .
doi: 10.18553/jmcp.2023.29.1.90
pubmed: 36580125
AbbVie Inc. HUMIRA
Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228–34. https://doi.org/10.1080/03610910902859574 .
doi: 10.1080/03610910902859574
Fitzgerald T, Zhdanava M, Pilon D, et al. Response to the Letter to the Editor: Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA. Dermatol Ther (Heidelb). 2023;13(11):2917–23. https://doi.org/10.1007/s13555-023-01017-8 .
doi: 10.1007/s13555-023-01017-8
pubmed: 37752408
Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLoS ONE. 2017;12(4): e0175099. https://doi.org/10.1371/journal.pone.0175099 .
doi: 10.1371/journal.pone.0175099
pubmed: 28426675
pmcid: 5398513
Luttropp K, Dalén J, Svedbom A, et al. Real-world patient experience of switching biologic treatment in inflammatory arthritis and ulcerative colitis—a systematic literature review. Patient Preference Adher. 2020;14:309–20. https://doi.org/10.2147/PPA.S238843 .
doi: 10.2147/PPA.S238843
Zhdanava M, Zhao R, Manceur AM, et al. Persistence and dose escalation during maintenance phase and use of nonbiologic medications among patients with ulcerative colitis initiated on ustekinumab in the United States. Crohns Colitis 360. 2023;5(3):otad045. https://doi.org/10.1093/crocol/otad045 .
doi: 10.1093/crocol/otad045
pubmed: 37671391
pmcid: 10476877
Bressler B, Jones J, In TSH, et al. Real-world persistence of ustekinumab in the treatment of inflammatory bowel disease. Adv Ther. 2023;40(10):4421–39. https://doi.org/10.1007/s12325-023-02611-0 .
doi: 10.1007/s12325-023-02611-0
pubmed: 37507652
Chiappetta MF, Viola A, Mastronardi M, et al. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther. 2021;21(11):1483–9. https://doi.org/10.1080/14712598.2021.1981855 .
doi: 10.1080/14712598.2021.1981855
pubmed: 34521307
Fumery M, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther. 2021;54(7):944–51. https://doi.org/10.1111/apt.16544 .
doi: 10.1111/apt.16544
pubmed: 34296456
Blesl A, Binder L, Högenauer C, et al. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther. 2021;54(5):667–77. https://doi.org/10.1111/apt.16478 .
doi: 10.1111/apt.16478
pubmed: 34151449
pmcid: 8453765
Pouillon L, Baumann C, Rousseau H, et al. Treatment persistence of infliximab versus adalimumab in ulcerative colitis: a 16-year single-center experience. Inflamm Bowel Dis. 2018;25(5):945–54. https://doi.org/10.1093/ibd/izy322 .
doi: 10.1093/ibd/izy322
Hoque S, Puenpatom A, Boccaletti S, et al. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol. 2020. https://doi.org/10.1136/bmjgast-2020-000476 .
doi: 10.1136/bmjgast-2020-000476
pubmed: 33199269
pmcid: 7670853
Zhdanava M, Ding Z, Manceur AM, et al. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn’s disease treated with ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(9):1215–25. https://doi.org/10.1080/03007995.2023.2246882 .
doi: 10.1080/03007995.2023.2246882
pubmed: 37563994
Privitera G, Pugliese D, Rapaccini GL, et al. Predictors and early markers of response to biological therapies in inflammatory bowel diseases. J Clin Med. 2021. https://doi.org/10.3390/jcm10040853 .
doi: 10.3390/jcm10040853
pubmed: 34575224
pmcid: 8469662
Zhdanava M, Zhao R, Manceur AM, et al. Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United States. J Manag Care Spec Pharm. 2024;30(2):141–52.
pubmed: 38308626
pmcid: 10839463
Awan H, Fatima U, Eaw R, et al. The efficacy of currently licensed biologics for treatment of ulcerative colitis: a literature review. Cureus. 2023;15(4): e37609. https://doi.org/10.7759/cureus.37609 .
doi: 10.7759/cureus.37609
pubmed: 37069838
pmcid: 10105519
Yiu TH, Ko Y, Pudipeddi A, et al. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;59(11):1312–34. https://doi.org/10.1111/apt.18006 .
doi: 10.1111/apt.18006
pubmed: 38651771
Das AK, Chang E, Paydar C, et al. Apremilast adherence and persistence in patients with psoriasis and psoriatic arthritis in the telehealth setting versus the in-person setting during the COVID-19 pandemic. Dermatol Ther (Heidelb). 2023;13(9):1973–84. https://doi.org/10.1007/s13555-023-00967-3 .
doi: 10.1007/s13555-023-00967-3
pubmed: 37392261
Gulliver W, Gooderham M, Reed C. Persistence and adherence to ixekizumab treatment in patients with moderate-to-severe psoriasis before and during COVID-19 pandemic: results from the Canadian Patient Support Program. J Am Acad Dermatol. 2022;87(3 suppl):AB91.
doi: 10.1016/j.jaad.2022.06.399
pmcid: 9465211